Sanara MedTech Inc.
Sanara MedTech Inc. (SMTI) Financial Performance & Income Statement Overview
Analyze Sanara MedTech Inc. (SMTI) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Sanara MedTech Inc. (SMTI) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Sanara MedTech Inc. SMTI financial performance.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $26.31M | $21.67M | $20.16M | $18.54M |
| Cost of Revenue | $2.25M | $1.99M | $2.009M | $3.00M |
| Gross Profit | $24.06M | $19.68M | $18.15M | $15.54M |
| Gross Profit Ratio | $0.91 | $0.91 | $0.90 | $0.84 |
| R&D Expenses | $2.41M | $1.36M | $985651.00 | $946298.00 |
| SG&A Expenses | $22.42M | $18.99M | $18.96M | $16.19M |
| Operating Expenses | $24.83M | $21.60M | $19.94M | $17.14M |
| Total Costs & Expenses | $27.08M | $23.60M | $23.04M | $20.13M |
| Interest Income | $21978.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $1.29M | $927577.00 | $644346.00 | $267336.00 |
| Depreciation & Amortization | $1.61M | $1.10M | $1.11M | $1.11M |
| EBITDA | $1.20M | -$851621.00 | -$1.78M | -$426287.00 |
| EBITDA Ratio | $0.05 | -$0.04 | -$0.09 | -$0.02 |
| Operating Income | -$374884.00 | -$1.92M | -$2.88M | -$1.60M |
| Operating Income Ratio | -$0.01 | -$0.09 | -$0.14 | -$0.09 |
| Other Income/Expenses (Net) | -$1.16M | -$959025.00 | -$644346.00 | -$201663.00 |
| Income Before Tax | -$1.54M | -$2.88M | -$3.53M | -$1.80M |
| Income Before Tax Ratio | -$0.06 | -$0.13 | -$0.18 | -$0.10 |
| Income Tax Expense | $162020.00 | $0.00 | $0.00 | -$34859.00 |
| Net Income | -$1.54M | -$2.86M | -$3.50M | -$1.76M |
| Net Income Ratio | -$0.06 | -$0.13 | -$0.17 | -$0.10 |
| EPS | -$0.18 | -$0.34 | -$0.41 | -$0.21 |
| Diluted EPS | -$0.18 | -$0.34 | -$0.41 | -$0.21 |
| Weighted Avg Shares Outstanding | $8.53M | $8.52M | $8.47M | $8.42M |
| Weighted Avg Shares Outstanding (Diluted) | $8.53M | $8.52M | $8.47M | $8.42M |
The company's financials show resilient growth, with revenue advancing from $18.54M in Q1 2024 to $26.31M in Q4 2024. Gross profit remained healthy with margins at 91% in Q4 2024 compared to 84% in Q1 2024. Operating income hit -$374884.00 last quarter, sustaining a consistent -1% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $1.20M. Net income rose to -$1.54M, while earnings per share reached -$0.18. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan